Brief: Maxcyte Signs Platform License Agreement With Adicet Bio
04/08/2025 13:52
Aug 4 (Reuters) - MaxCyte Inc MXCT.O: MAXCYTE SIGNS PLATFORM LICENSE AGREEMENT WITH ADICET BIO MAXCYTE INC - ADICET BIO OBTAINS RIGHTS TO USE MAXCYTE'S TECHNOLOGY Source text: ID:nGNXbxV8JV Further company coverage: MXCT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsCell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted
Brief: MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MaxCyte Inc reports results for the quarter ended June 30 - Earnings Summary
MaxCyte Q2 revenue beats estimates
MaxCyte Inc expected to post a loss of 9 cents a share - Earnings Preview